Rainbow Children’s Medicare IPO: the initial public offer (IPO) of Rainbow Children’s Medicare IPO opened on Wednesday April 27, 2022. The IPO of three days RS 1 580.85 will criterion will close on April 29. The total size of the introduction, Fresh The problem includes RS 280 Core and a sales offer of Rs 1300.85 crores. The company, which manages a pediatric hospital channel, obstetrics and multi -specialty gynecology, has retained a price strip of 516 – 542 Rs for this offer. An investor can request a minimum lot, which has 27 shares.

While the IPO of three days of Rainbow Children’s Medicare opens today, Zee Business Maning Anil Singhvi and brokerage houses recommend what investors should do with this problem and how to approach the IPO . Here is what they recommend:

Speaking of positive, he said that the company offers good financial history, has a solid cash flow with low debt and is delivered with reasonable assessments.

Swastika Investmart

The company has followed a financially disciplined model, focusing on profitable growth. In the future, they can seek to extend their hospital network thanks to the acquisition of assets in frost or to the development of Greenfield assets. The profitability of 9 months enclosed on December 31, 2021 increased substantially to 126.41 crores, against 38.53 crores during the same period of the last taxman.

We believe that this exponential increase in profits may not continue in the future. However, the specialized nature of business, the experienced management team, the proven ability to attract, train and retain high caliber health professionals, under the penetration of hospitals in India, makes this problem of good choice . Thus, we give a note “subscribe” to this long-term IPO.

Marwadi financial services

Given the EPS TTM (December 21) of RS 12.56 On a public basis, the company will register for a p / e of 43.16x with a market capitalization of RS.55,013 min while its peers namely Apollo Hospital Enterprise Ltd and Fortis Healthcare Ltd is negotiated respectively in PE of 77.3x and 56.9x. We provide a “under accused” note to this IPO because the company is a leading multi-specialty health channel with strong clinical expertise in the management of complex diseases. In addition, it is available to a reasonable assessment compared to its peers.

Earlier Tuesday, the company collected near Rs 470 crosses with anchoring investors before its first public public call (IPO).